A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology

British Journal of Dermatology

Volumn 137, Issue 4, 1997, Pages 568-576

  Meingassner, J G ^a   Grassberger, M ^a   Fahrngruber, H ^a   Moore, H D ^a   Schuurman, H ^b   Stutz A ^a  

^a Novartis Research Institute   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CLOBETASOL PROPIONATE; MACROLIDE; PIMECROLIMUS; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTACT DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SKIN INFLAMMATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOSPORINE; DERMATITIS, ALLERGIC CONTACT; FEMALE; GLUCOCORTICOIDS; GRAFT SURVIVAL; GRAFT VS HOST REACTION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, INBRED STRAINS; RATS; RATS, INBRED STRAINS; SKIN; SWINE;

EID: 0030827498     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb03788.x     Document Type: Article

References (40)

1. Hellgren L. Psoriasis. The Prevalence in Sex, Age and Occupational Groups in Total Populations in Sweden. Morphology, Inheritance and Association with Other Skin and Rheumatic Diseases. Stockholm: Almquist and Wiksell, 1976: 19-53.
2. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. Br J Prevent Social Med 1976; 30: 107-14.
3. US National Health Survey 1971-74. Vital end Health Statistics. Series II, No. 212.
4. Schultz LF. The epidemiology of atopic dermatitis. Monogr Allergy 1993; 31: 9-28.
5. Saurat JH. Dermatite atopique de l'enfant. Ann Nestle 1987; 45: 9-25.
6. Rajka G. Natural history and clinical manifestations of atopic eczema. Clin Rev Allergy 1986; 4: 3-26.
7. Johnson ML. Prevalence of dermatologic disease among persons 1-74 years of age in the United States. Advance Data from Vital and Health Statistics of the National Center for Health Statistics 1977; 4.
8. Camp RDR. Psoriasis. In: Textbook of Dermatology (Champion RH, Burton JL, Ebling FJG, eds), 5th edn. Oxford: Blackwell Scientific Publications, 1992; 1391-458.
9. Hay RJ, Champion RH, Greaves MW. Systemic therapy. In: Textbook of Dermatology (Champion RH, Burton JL, Ebling FJG, eds), 5th edn. Oxford: Blackwell Scientific Publications, 1992; 2927-60.
10. Breathnach SM. Drug reactions. In: Textbook of Dermatology (Champion RH, Burton JL, Ebling FJG, eds), 5th edn. Oxford: Blackwell Scientilic Publications, 1992; 2961-3036.
11. Griffiths CEM, Wilkinson JD. Topical therapy. In: Textbook of Dermatology (Champion RH, Burton JL, Ebling FJG, eds), 5th edn. Oxford: Blackwell Scientilic Publications, 1992; 3037-84.
12. Robertson DB, Maibach HI. Adverse systemic effects of topical corticoids. In: Topical Corticosteroids (Maibach HI, Surber C, eds). Basel: Karger, 1992; 163-9.
13. Sillevis Smitt JH, Winterberg DH. Topical corticosteroids in children: local and systemic effects. In: Topical Corticosteroids (Maibach HI, Surber C, eds). Basel: Karger, 1992; 196-209.
14. Champion RH, Parish WE. Atopic dermatitis. In: Textbook of Dermatology (Champion RH, Burton JL, Ebling FJG, eds), 5th edn. Oxford: Blackwell Scientilic Publications, 1992; 589-610.
15. Griffiths CE, Powles AV, McFadden J, et al. Long-term cyclosporin for psoriasis. Br J Dermatol 1989; 120: 253-60.
16. Mihatsch MJ, Wollf K. Consensus conference on cyclosporin A for psoriasis, February 1992. Br J Dermatol 1992; 126: 621-3.
17. Sowden JM, Berth Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137-40.
18. van Joost T, Heule F, Stolz E, Beukers R. Short-term use of cyclosporin A in severe psoriasis. Br J Dermatol 1986; 114: 615-20.
19. Griffiths CE, Powles AV, Baker BS, et al. Topical cyclosporin and psoriasis (letter). Lancet 1987; i: 806.
20. Berth Jones J, Hutchinson PE. Vitamin D analogues and psoriasis. Br J Dermatol 1992; 127: 71-8.
21. Rappersberger K, Meingassner JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996; 106: 701-10.
22. Meingassner JG, Stütz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases. J Invest Dermatol 1992; 98: 851-5.
23. Ford WL, Burr W, Simonsen M. A lymph node assay for the graft-versus-host activity of rat lymphoid cells. Transplantation 1979; 10: 258-66.
24. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporin improves psoriasis in a double-blind study. JAMA 1986; 256: 3110-16.
25. Griffiths CE, Powles AV, Leonard JN, et al. Clearance of psoriasis with low dose cyclosporin. Br Med J Clin Res Ed 1986; 293: 731-2.
26. van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease (letter). Arch Dermatol 1987; 123: 166-7.
27. Ross JS, Camp RD. Cyclosporin A in atopic dermatitis. Br J Dermatol 1990; 122 (Suppl. 36): 41-5.
28. Higgins EM, McLelland J, Friedmann PS, et al. Oral cyclosporin inhibits the expression of contact hypersensitivity in man. J Dermatol Sci 1991; 2: 79-83.
29. Groisser DS, Griffiths CE, Ellis CN, Voorhees JJ. A review and update of the clinical uses of cyclosporine in dermatology. Dermatol Clin 1991; 9: 805-17.
30. Mrowietz U. The enigma of cyclosporin A treatment for psoriasis: systemic efficacy vs. topical non-responsiveness. A review. Acta Derm Venereol (Stock) 1992; 72: 321-6.
31. Surber C, Itin P, Buchner S. Clinical controversy on the effect of topical ciclosporin: what is the target site? Dermatology 1992; 185: 242-5.
32. de Prost Y, Bodemer C, Teillac D. Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Derm Venereol (Stockh) 1989; Suppl. 144: 136-8.
33. de Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol (Stockh) 1991; 71: 452-4.
34. Meingassner JG, Baumann K, Grassberger M, et al. Topical activity of the immunosuppressive macrolide SDZ 281-240 in animal models of allergic contact dermatitis (abstract). J Invest Dermatol 1994; 102: 599.
35. Marks R. Adverse side effects from the use of topical corticosteroids. In: Topical Corticosteroids (Maibach HI, Surber C, eds). Basel: Karger, 1992: 170-83.
36. Burton JL. Disorders of connective tissues. In: Textbook of Dermatology (Champion RH, Burton JL, Ebling FJG, eds), 5th edn. Oxford: Blackwell Scientific Publications, 1992; 1763-826.
37. Meingassner JG, Hekm A, Vit P et al. SDZ ASM 981 - a novel anti-inflammatory macrolactam - does not induce skin atrophy. Australasian J Dermatol 1997, 38(Suppl. 2), abstract 5243.
38. Mrowietz U, Bräutigam M, Gräber M et al. Topical treatment with the anti-inflammatory macrolactam SDZ ASM 981 suppresses plaque-type psoriasis. Australasian J Dermatol 1997, 38(Suppl. 2), abstract 2056.
39. Van Leent EJM, Gräber, M, Thurston M et al. Topical treatment with the macrolactam SDZ ASM 981 is effective in atopic dermatitis. Australasian J Dermatol 1997, 38(Suppl. 2), abstract 4134.
40. Qucille-Roussel C, Graeber M, Wagenaar A et al. Topical treatment with the anti-inflammatory macrolactam SDZ ASM 981 inhibits established nickel contact dermatitis. Australasian J Dermatol 1997, 38(Suppl. 2), abstract 3039.